Connect with us
At Swiss Biotech Day in Basel, early discussions lacked data, revealing mixed sentiment despite official reports showing strong growth. Switzerland’s biotech sector reached record revenues, stable...
Johnson & Johnson has EU approval for nipocalimab for generalized myasthenia gravis, showing superior control and sustained benefits. Sanofi reported a safer protein COVID-19 vaccine versus...
Novartis will acquire U.S.-based Avidity Biosciences for $12 billion, expanding into advanced RNA-based therapies. The $72-per-share tender offer, a 46% premium, was unanimously approved. Avidity will...
Novartis plans to sell Morphosys' business, acquired for €2.7 billion in 2023, affecting 330 employees as it closes two factories by 2025. Initially aimed at boosting...
A U.S. judge ruled that Novartis lacked grounds to suspend the launch of MSN's generic version of Entresto but ordered a temporary production halt pending Novartis'...
Zolgensma, Novartis' gene therapy for SMA, remains the world's most expensive medicine, priced between $1.2 million and $2.1 million per dose. Despite its high cost, it's...
Novartis CEO said that the pharmaceutical company's strategy involves not exceeding acquisitions of more than $5 billion. The agreement with Cytokinetics meant a larger investment, since,...
The pharma sector faces a setback in sustainability, as AstraZeneca, Novartis, and Amgen, previously included in the Dow Jones Sustainability Index, are omitted in the latest...
Novartis has acquired global rights to develop, manufacture, and commercialize Leqvio under a licensing and collaboration agreement with Alnylam Pharmaceuticals, which is a leader in RNA...
Sandoz was spun off from Novartis on October 4th, following its listing on the Swiss SIX stock exchange. Sandoz works with generic or biosimilar medicines with...